The Korean study published online in Stem Cell Reports features twelve months of post-transplant follow-up data from four Asian patients; two with Stargardt’s macular degeneration (SMD) and two with dry age-related macular degeneration (AMD).
with respect mf, you're crazy to continue to throw money here. An almost 20% discount to closing after a reverse split. Obscene. Unless everyone in management is taking a 20 % salary cut and no free shares for a couple years. naw, i didn't think so.
this has been deleted twice. i'll try it this way
I believe O'real has an exclusive on dermatolgic use for cosmetics. There may be an ocular model soon that could also be used by cosmetic companies as well.
you're mistaken about ONVO. they are not and have no intention of being a drug company. The ability to test reaction and toxicity in real human cells, particularly liver and kidney has breathtaking potential and can save billions in failed drug research. Not to mention the expense of developing a successful assay which is why pharma by and large leaves that to others to develop and then licenses. Printing whole organs is still science fiction but will happen and this company, I believe, will be the ONE. And as you noted, then there is cosmetics, veterinary medicine.
thx alex, but Scottrade has been good to me with rare exception. and since I had no intent to sell any it was a non event for my portfolio. Awaiting news soon that should jump the price a bit.
He's doing well but.......wwwDOTyoutubeDOTcom/watch?v=9UIixln4h2I
It happens. there are more, be happy but be real. We are still in the 2nd inning of a 9 inning game.
that this gets beat down for a month just before an announcement such as this is released? Where would the price be going if we held or built on the 6.50 close in mid February? This biotech/pharma sector is the most corrupt and manipulated one ever. I do hope some institutional shorts get burned but I suspect they saw this coming.